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Background: Granulocyte colony-stimulating factor (G-CSF) promotes proliferation, survival, and differentiation of
myeloid-linage leukemic cells, as well as normal hematopoietic cells. Terminal granulocytic differentiation can be
induced in acute promyelocytic (APL) cell line HT93A by G-CSF and all-trans retinoic acid (ATRA). Because the
detailed mechanism has never been shown, we investigated the signal transduction pathway in granulocytic
differentiation by G-CSF, alone or in combination with ATRA.
Methods: HT93A cell viability and growth were investigated by trypan blue exclusion assay. Cell differentiation was
assessed by CD11b and CD34 expressions. Intracellular protein expressions were also evaluated by flow cytometry
after fixation and permeabilization.
Results: ATRA (100 nM) induced granulocytic differentiation (upregulation of CD11b and downregulation of CD34)
and the effect was potentiated by addition of G-CSF, while G-CSF alone had no effect on HT93A cells. The addition
of G-CSF to ATRA had little or no effect on NB4 and THP-1 cells in comparison to ATRA alone. G-CSF receptor
expression was reduced by ATRA treatment in a time-dependent manner. After 5 days’ incubation with ATRA,
the expression levels of signal transducer and activator of transcription (STAT) 3, and phosphorylated STAT3 and
STAT5, were significantly reduced. STAT5 was strongly activated by G-CSF stimulation in ATRA-pretreated cells in
comparison to untreated cells. In contrast, STAT3 showed no response to G-CSF. Janus kinase (JAK) inhibitor
ruxolitinib (320 nM) had little or no effect on ATRA-induced differentiation, but eliminated the enhancing effect of
G-CSF, as evidenced by the levels of CD11b and CD34 expression. These results suggest G-CSF activates STAT5
through the JAK pathway in combination with ATRA, resulting in myeloid differentiation in HT93A cells.
Conclusions: In conclusion, activation of the JAK-STAT pathway is likely essential for inducting differentiation in the
APL cell line HT93A; thus, monitoring its expression and activation is important for predicting clinical efficacy and
understanding the mechanisms of cytokine-dependent myelopoiesis, proliferation, and differentiation of acute
myeloid leukemia.
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Granulocyte colony-stimulating factor (G-CSF) is a myeloid
growth factor that promotes proliferation, survival, and
differentiation of myeloid-lineage leukemic cells, as well as
normal hematopoietic cells [1,2]. Clinical studies have
revealed that G-CSF is an effective promoter of granulocyte
recovery [3]. G-GSF has also been used for its priming
effect, enhancing the sensitivity of leukemia progenitor cells
to cytotoxic agents with or without all-trans retinoic acid
(ATRA) to improve therapeutic outcomes in acute myeloid
leukemia (AML) [4-7].
Studies in various cell lines have revealed that G-CSF
functions through the Janus kinase (JAK)-signal trans-
ducer and activator of transcription (STAT) pathway
[8-10]. STAT3 and STAT5 are the major factors that
would be affected by G-CSF treatment [11-13]. Although
basic studies of G-CSF in various in vitro systems have
been performed [8-17], the efficacy and mechanisms of
G-CSF, alone or in combination with ATRA, are not well
understood in the context of differentiation induction.
Acute promyelocytic leukemia (APL) is characterized
by a balanced reciprocal translocation between chromo-
some 15 and 17, resulting in fusion of the promyelocytic
leukemia and retinoic acid receptor alpha genes [18-20].
ATRA has become the first-line treatment for patients with
APL due to its specific effect on differentiation induction
and high complete remission rate [21,22]. Established
by Kishi et al., APL cell line HT93A carries t(15;17), is
sensitive to ATRA, and its differentiation is enhanced by
treatment with G-CSF [23,24].
In this study, we examined the differentiation mechan-
ism of ATRA and G-CSF, alone or in combination, in
HT93A cells. Our data suggest enhanced differentiation
induction through the JAK-STAT pathway is induced by
combination treatment with ATRA and G-CSF in AML.
Results
Differentiation of HT93A cells by ATRA and G-CSF
After treatment with 100 nM ATRA for 7 days, expression
of major differentiation marker CD11b increased, while
primitive marker CD34 decreased in HT93A cells
(Figure 1A). Treatment with G-CSF alone did not affect
these markers; however, ATRA plus G-CSF potentiated
CD11b upregulation and CD34 downregulation in
comparison to ATRA alone. Differentiation in NB4 and
THP-1 cells was induced by ATRA; however, G-CSF alone
or in combination with ATRA had little or no effect on
these cell lines. HT93A alone showed high levels of CD34
and G-CSF receptor expression (Figure 1A and B).
G-CSF activates STAT5 rather than STAT3 in the presence
of ATRA
After treatment with 100 nM ATRA for 5 days, the
expression levels of STAT3, STAT5A, STAT5B, andphosphorylated STAT3 and STAT5 were evaluated by
intracellular staining followed by flow cytometry as
described in the Materials and methods. ATRA alone
inhibited expression of STAT3 (Figure 2A and B).
Furthermore, phosphorylated STAT3 and STAT5 were
also reduced (Figure 3A-C). After stimulation with
50 ng/mL G-CSF for 60 min, STAT5 phosphorylation
was observed in ATRA-treated cells, although the response
was not significant in untreated cells (Figure 3A and C).
In contrast, STAT3 phosphorylation was unaltered by
G-CSF stimulation in untreated and ATRA-treated cells
(Figure 3A and B).
Growth inhibition by Jak inhibitor ruxolitinib
Differentiation induction by G-CSF likely occurs via the
JAK-STAT signaling pathway; therefore, we investigated
whether JAK is associated with G-CSF-induced gran-
ulocytic differentiation in HT93A cells. We applied
the JAK inhibitor ruxolitinib, which is used to treat
myelofibrosis [25]. Growth inhibition was assessed in
order to determine the optimal concentration of ruxolitinib.
After dose titration of ruxolitinib for 7 days, cell growth
was evaluated by trypan blue exclusion. HT93A cells were
sensitive to ruxolitinib, which inhibited growth in a
dose-dependent manner, with a significant difference
in the concentration of more than 320 nM compared
to control (Figure 4). Thus, we chose to use 320 nM
ruxolitinib for subsequent experiments.
Ruxolitinib inhibits STAT5 activation by G-CSF in the
presence of ATRA
We assumed that the potentiation effect of G-CSF
occurs via the JAK-STAT5 pathway in the presence of
ATRA; thus, we sought to determine whether the JAK
inhibitor ruxolitinib inhibits G-CSF-induced STAT5
activation. After treatment with 100 nM ATRA with or
without 320 nM ruxolitinib for 5 days, HT93A cells were
stimulated with 50 ng/mL G-CSF for 60 min. The
expression levels of phosphorylated STAT5 were evaluated
by intracellular staining followed by flow cytometry.
As shown in Figure 5A and B, HT93A cells treated
with ATRA plus ruxolitinib showed significantly lower
expression level of phosphorylated STAT5 in comparison
to those treated with ATRA alone.
G-CSF-induced differentiation is abrogated by addition of
ruxolitinib
We next investigated the effect of ruxolitinib with ATRA
alone or in combination with G-CSF on cell differentiation.
HT93A cells were treated with 100 nM ATRA, with or
without 50 ng/mL G-CSF, in the presence or absence of
ruxolitinib for 7 days. ATRA in combination with G-CSF
induced CD11b expression and inhibited CD34 expression
in comparison to treatment with ATRA alone (Figure 6A
Figure 1 (See legend on next page.)
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Figure 1 Granulocytic differentiation and G-CSF receptor expression. Differentiation profile of surface antigen expression in HT93A, NB4
and THP-1 cells (A). These cell lines were treated with 100 nM ATRA and 50 ng/mL G-CSF, alone or in combination, for 7 days (HT93A) and 48 h
(NB4 and THP-1). Because THP-1 cells express high levels of CD11b in the control, CD11b expression is reported as the mean fluorescence
intensity (MFI). Expression of G-CSF receptor in HT93A, NB4, and THP-1 cells (B). HT93A specifically exhibited ATRA-induced CD11b expression
and a decline in CD34, with strong G-CSF receptor expression. Expression profiles of CD11b, CD34, and G-CSF receptor were evaluated by flow
cytometry. Experiments were performed twice or three times, each yielding similar results.
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on ATRA-induced differentiation, enhancement of ATRA
by G-CSF was almost completely abrogated by ruxolitinib,
as shown by changes in CD11b and CD34 expression
(Figure 6A and B).
G-CSF receptor is downregulated by ATRA
HT93A cells were treated with 100 nM ATRA with or
without 50 ng/mL G-CSF for 7 days and expression
levels of G-CSF receptor on the cell surface were investi-
gated using flow cytometry. G-CSF receptor expression
was significantly downregulated by ATRA, regardless ofFigure 2 Flow cytometry to assess expression of STATs in HT93A cell
STAT5A, and STAT5B expression was evaluated. Histograms (A) and bar gra
presence or absence of ATRA. Experiments were independently repeated tthe presence or absence of G-CSF (Figure 7A and B);
expression of the G-CSF receptor was repressed in a
time-dependent manner (Figure 7C). G-CSF alone had no
effect on G-CSF receptor expression (Figure 7A and B).
Discussion
Our study demonstrated that G-CSF potentiates
ATRA-induced granulocytic differentiation by enhancing
STAT5 activation through the JAK/STAT pathway in
HT93A cells. The JAK-STAT pathway, especially JAK1/2
and STAT3/5, is essential to the mechanism of G-CSF
efficacy [11-13,26,27]. We showed that STAT5 activations. After treatment with or without 100 nM ATRA for 5 days, STAT3,
phs (B) represent STAT3, STAT5A, and STAT5B expression in the
hree times and results are shown as mean ± SD. NS not significant.
Figure 3 Flow cytometry analysis of phosphorylated STAT expression in HT93A cells. After treatment with or without 100 nM ATRA for
5 days, expression of phosphorylated STATs was evaluated before or after 50 ng/mL G-CSF stimulus for 60 min. Histograms (A) and bar graphs
represent phosphorylated STAT3 (B) and STAT5 (C) expression. Experiments were independently repeated three times and results are shown as
mean ± SD. NS not significant.
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with ATRA. We also found that STAT5 activation was
associated with cell differentiation, as shown by the altered
expression of surface antigens in HT93A cells. Although
STAT3 activation by G-CSF has been well studied in
various leukemia cell lines, we did not observe it here in
HT93A cells. While most prior studies of G-CSF have
focused on the activation of STAT3 or STAT5 in leukemia
cell lines, Tanaka et al. [28] demonstrated that G-CSFactivates both STAT3 and STAT5 in humanized mice,
suggesting the critical role of STAT3 and STAT5 for
normal granulocytic differentiation from hematopoietic
stem cells. Therefore, activation of both STAT3 and
STAT5 is likely required for granulocytic differentiation.
We assumed that STAT3 might already be activated in
HT93A, and there might be little margin for additional
response in the presence of G-CSF. Similar to our findings,
APL cell line UF-1 is resistant to ATRA but differentiation
Figure 4 Growth inhibition by ruxolitinib in HT93A cells. After
treatment for 7 days, growth inhibition was determined by trypan blue
exclusion assay. Ruxolitinib inhibits cell growth in a dose-dependent
manner. More than 320 nM ruxolitinib significantly inhibited growth.
Experiments were independently repeated three times and results are
shown as mean ± SD. *p < 0.05 vs. control.
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studies investigated STAT3 activation, but failed to explain
the contribution of STAT3 to G-CSF-induced granulocytic
differentiation in combination with ATRA [29,30]. We
believe ATRA promotes STAT5 activation by G-CSF, but
not STAT3. However, we did not evaluate JAK-related
pathways other than JAK-STAT, such as ERK, PI3K, AKT,
and MAPK. Other JAK-related signaling pathways might
contribute to granulocytic differentiation in HT93A cells.
We could not determine why STAT5 was activated by
G-CSF in the presence of ATRA in our study. We
hypothesized that ATRA may up-regulate STAT or
G-CSF receptor expression; however, our data showed
that STAT3 and G-CSF receptor expression were reduced
by ATRA treatment. These phenomena may be due to a
negative feedback mechanism. Indeed, multiple negative
feedback mechanisms such as reduction of the cytokine
receptor, the presence of suppressor of cytokine signal
proteins, and inhibition of STAT DNA-binding activity
has been suggested [13,31]. Although additional studies
are needed to resolve the mechanism underlying the
combined effect of G-CSF and ATRA, we assume that
any factor that would be affected by ATRA treatment
may lie between the cascade of G-CSF receptor and
STAT activation.
We used the JAK inhibitor ruxolitinib to verify the
requirement of JAK for STAT activation. Inhibition of
JAK1, JAK2, and JAK3 as indicated by IC50 is reported to
be 3.3 nM, 2.8 nM, and 428 nM ruxolitinib, respectively
[32]. Consistent with these differences in sensitivity, 320
nM ruxolitinib was considered sufficient for inhibition of
JAK1 and JAK2, which are critical for G-CSF signaling
[32]. Differentiation of HT93A cells treated with ATRA
and G-CSF was abrogated by adding ruxolitinib; the JAKinhibitor reduced differentiation to levels obtained
with ATRA alone. However, ruxolitinib did not inhibit
ATRA-induced differentiation. These results suggest that
the major mechanism of G-CSF-induced granulocytic
differentiation is activation of the JAK-STAT pathway,
although this pathway is not important for ATRA-induced
differentiation.
Because other ATRA-sensitive AML cell lines are not
capable of responding to G-CSF even in the presence of
ATRA, we investigated the specificity of the HT93A
response in comparison to NB4 and THP-1. We suggest
the difference is attributable to the unique characteristics
of HT93A. Compared to NB4 or THP-1, HT93A cells
exhibit distinct degrees of differentiation via CD34
positivity, suggesting their immaturity as myeloid-linage
progenitor cells. It should be noted that G-CSF specifically
affects progenitor cells that correspond to a specific
granulocytic differentiation degree as shown by the
CD33+/CD34+ immunophenotype [33]. Interestingly,
HT93A cells exhibit a differentiation stage equivalent
to that of the progenitor cells, which are the major
target of G-CSF [24,34]. The differential response is
likely due to the differences in G-CSF receptor expression
in these cell lines, in addition to differences in CD34
expression. Indeed, G-CSF receptor expression was
repressed in ATRA-treated HT93A cells, as was granulo-
cytic differentiation as indicated by the reduction in CD34
expression. These findings demonstrate the utility of
HT93A cells as a model for understanding the effects of
G-CSF and ATRA.
Conclusions
In conclusion, STAT5 activation (not STAT3) is likely
essential for G-CSF-induced granulocytic differentiation in
HT93A. This unique cell line mimics normal progenitor
cells and may become a useful model for analyzing the
effects of cytokine-dependent myelopoiesis, proliferation,
and differentiation of hematopoietic cells.
Materials and methods
Reagents
ATRA was purchased from Sigma (St. Louis, MO),
dissolved in ethanol to 2 mM, and stored at −20°C in
the dark. The final concentration of ethanol (≤0.05%) did
not affect cell viability or differentiation. Recombinant
human G-CSF (Filgrastim) was obtained from Kyowa
Hakko Kirin Co, Ltd. (Tokyo, Japan), dissolved in
phosphate-buffered saline (PBS) to prepare the stock
solution, and stored at −20°C. The JAK inhibitor ruxolitinib
was purchased from ChemScene (Monmouth Junction,
NJ) and dissolved in dimethyl sulfoxide to 10 mM.
Primary antibodies, phycoerythrin (PE)-conjugated mouse
anti-human CD11b IgG2α, fluorescein isothiocyanate
(FITC)-conjugated mouse anti-human CD34 IgG1, and
Figure 5 (See legend on next page.)
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Figure 5 After treatment with 100 nM ATRA with or without 320 nM ruxolitinib for 5 days, HT93A cells were stimulated with 50 ng/mL
G-CSF for 60 min. Expression of phosphorylated STAT5 was evaluated by intracellular staining and analyzed by flow cytometry. Ruxolitinib-treated
HT93A cells showed significantly lower phosphorylated STAT5 expression. Histograms (A) and bar graphs (B) represent phosphorylated STAT5
expression. Experiments were independently repeated three times and results are shown as mean ± SD.
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IgG1 antibody were purchased from Becton-Dickinson
(San Jose, CA). Non-binding mouse IgG-PE and IgG-FITC
isotype antibodies (Becton-Dickinson) were used as
controls. Antibodies for intracellular staining, rabbitFigure 6 Abrogation of G-CSF-induced differentiation with ruxolitin
50 ng/mL G-CSF, in the presence or absence of ruxolitinib for 7 days. CD11b
on ATRA-induced alterations of CD11b and CD34, but abrogated the enhanci
and results are shown as mean ± SD. *p < 0.05 vs. control; #p < 0.05 vs. ATRA.anti-STAT3 (#GTX108630), anti-STAT5A (#GTX103750),
anti-phosphorylated STAT3 (Y705; #GTX118000), and
anti-phosphorylated STAT5 (Y694; #GTX13593) poly-
clonal antibodies, were purchased from GeneTex (Irvine,
CA); anti-STAT5B polyclonal antibody (#bs-4254R) wasib. HT93A cells were treated with 100 nM ATRA, with or without
(A) and CD34 (B) expression are shown. Ruxolitinib had little or no effect
ng effect of G-CSF. Experiments were independently repeated three times
Figure 7 Alteration of G-CSF receptor expression with ATRA. HT93A cells were treated with 100 nM ATRA with or without 50 ng/mL G-CSF
for 7 days. (A and B) G-CSF receptor expression was significantly downregulated by ATRA regardless of the presence or absence of G-CSF. G-CSF
alone had no effect on G-CSF receptor expression. (C) The alteration of G-CSF receptor was time-dependent. Experiments were independently
repeated three times and results are shown as mean ± SD. *p < 0.05 vs. control; #p < 0.05 vs. ATRA.
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IgG secondary antibody was obtained from Kirkegaard &
Perry Laboratories (Gaithersburg, MD). Non-binding
rabbit IgG (GeneTex) was used instead of primary anti-
body as negative control.
Cell culture
HT93A, a human APL cell line established from the
peripheral blood of a patient with APL [23], was
provided by Dr. Kenji Kishi (Shibata Hospital, Shibata,
Japan) and Dr. Yuko Sato (National Center for Global
Health and Welfare, Japan). HT93A, NB4 (APL), and
THP-1 (acute myelomonocytic leukemia) cells weremaintained in RPMI-1640 medium (Sigma) supple-
mented with 10% heat-inactivated fetal bovine serum
(Gibco-BRL, Grand Island, NY), 100 U/mL penicillin,
and 100 μg/mL streptomycin (Gibco-BRL) at 37°C in a
humidified atmosphere (5% CO2 in air).
Growth inhibition
HT93A cell viability was investigated by trypan blue
exclusion assay. Cells that stained negative and positive
with trypan blue were considered as viable and dead,
respectively. Growth inhibition was expressed as a ratio of
the number of viable cells in each treatment group to the
control group.
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Differentiation induction was confirmed by surface
marker expression. Myeloid maturation was analyzed by
FACSCalibur cytometry (Becton-Dickinson) with CD11b,
CD34, and G-CSF receptor antibodies as described with
minor modifications [24,33,34]. In brief, approximately
1 × 106 cells were washed with PBS containing 2.5% fetal
bovine serum and 0.5% NaN3 (PBSF) and stained
with PE-conjugated mouse anti-human CD11b IgG2a,
PE-conjugated mouse anti-human G-CSF receptor
IgG1, and FITC-conjugated mouse anti-human CD34
IgG1 for 30 min at 4°C in the dark. Cells were
washed twice with PBSF and analyzed by flow cytometry
with a minimum acquisition of 10,000 events. Non-
binding mouse IgG-PE isotype antibodies or non-binding
mouse IgG-FITC isotype antibodies were used as controls.
Intracellular staining
Flow cytometry analysis was performed to analyze intracel-
lular protein expression after fixation and permeabilization
[35,36]. Cells were collected by centrifugation and fixed
with 4% formaldehyde for 10 min at 37°C. After fixation,
cells were permeabilized by adding ice-cold 100% methanol
to a final concentration of 90% and incubated at −20°C for
30 min. After washing twice with PBSF, cells were stained
with each primary antibody for 30 min at 4°C, followed by
staining with FITC-conjugated secondary antibody for
30 min at 4°C in the dark. Cells were washed twice with
PBSF and analyzed by flow cytometry with a minimum
acquisition of 10,000 events. Expression of each protein is
reported as mean fluorescence intensity (MFI).
Statistical analysis
Experiments were independently repeated three times,
and results shown are the mean ± standard deviation
(SD). Data were analyzed using paired Student’s t-test,
and p < 0.05 was considered statistically significant.
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